



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

High-dose praziquantel therapy for cerebral sparganosis

Gonzenbach, R R ; Kong, Y ; Beck, B ; Buck, A ; Weller, M ; Semmler, A

DOI: <https://doi.org/10.1007/s00415-013-6901-7>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-79903>

Journal Article

Accepted Version

Originally published at:

Gonzenbach, R R; Kong, Y; Beck, B; Buck, A; Weller, M; Semmler, A (2013). High-dose praziquantel therapy for cerebral sparganosis. *Journal of Neurology*, 260(5):1423-1425.

DOI: <https://doi.org/10.1007/s00415-013-6901-7>

High dose praziquantel therapy for cerebral sparganosis

Roman R. Gonzenbach¹, Yoon Kong², Bernhard Beck³, Alfred Buck⁴, Michael Weller¹,
Alexander Semmler¹

¹University Hospital Zurich, Department of Neurology, Zürich, Switzerland

²Sungkyunkwan University School of Medicine, Department of Molecular Parasitology,
Korea

³University Hospital Zurich, Department of Infectiology, Zürich, Switzerland

⁴University Hospital Zurich, Department of Radiology, Zürich, Switzerland

Corresponding author: Roman Gonzenbach, Department of Neurology, University Hospital
Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland, e-mail:
roman.gonzenbach@usz.ch, phone: +41 (0)44 255 55 11, fax: +41 (0)44 255 43 80

Keywords: Cerebral sparganosis, Spirometra, wandering lesion, Praziquantel,
ethylcholine PET

Abstract: Cerebral sparganosis is a rare parasitic infection of the brain caused by the
tapeworm *Spirometra* spp. Surgical removal is the only therapy with documented efficacy.
We report a case of a patient with a biopsy-confirmed sparganosis, where an initially false
diagnosis with futile treatment, transient loss to follow up and refusal of suggested surgery
allowed documenting the migration track of the wandering sparganum through the brain
parenchyma over 2.5 years by MRI. We treated the patient with a high dose regimen of
praziquantel since the patient refused a surgical intervention. Following medication, imaging
signs of active cerebral sparganosis receded, specific anti-sparganum IgG antibody levels
normalized and clinical symptoms improved, suggesting that the sparganum had been
eradicated.

Dear Sirs,

A 39-year-old Bangladeshi man was admitted to our hospital with a first generalized epileptic seizure. Brain MRI showed multiple ring-enhancing lesions with perifocal edema (A and G, February 2008). CSF analysis showed 8 cells/ μ l and normal protein, glucose and lactate levels. Serum and CSF serological tests were negative for a broad range of parasites, fungi and bacteria.

The patient was suspected to have neurocysticercosis and was treated with albendazole (400mg bi-daily for 30 days). However, follow up MRI showed new, adjacent lesions with ring- and tunnel-shaped enhancement; and punctate calcifications in the left parieto-occipital area in the CT (B,H and M, December 2009), suggesting that the treatment had been ineffective. We therefore performed a brain biopsy (with prior MRI for the localization of the sparganum, C and I, February 2010), which revealed a degenerated cyst containing membrane shaped structures with multiple foci of calcification. PCR was positive for *Spirometra erinaceieuropaei*, leading to the diagnosis of cerebral sparganosis.

Surgical removal of the parasite is the treatment of choice as standard antihelminthic therapy is considered ineffective in sparganosis [1-3]. The repeated MRI indicated that the lesion had been wandering again (D and J). An ethylcholine PET showed a defined region with increased tracer uptake most likely indicating the current location of the sparganum (N). However, the patient refused the recommended stereotactic surgery. We therefore treated the patient with a high dose regimen of praziquantel (3 x 25 mg/kg body weight daily) for 7 days combined with cimetidine (3 x 400 mg daily) and a high carbohydrate diet to increase plasma levels of praziquantel [4]. The treatment was well tolerated.

Follow up MRI 3 months and 11 months later showed drastically improved findings and the ethylcholine PET had normalized (E, F, K, L, O and P). Anti-sparganum antibody levels were determined from preserved CSF and serum samples by a specific ELISA [5]. Before therapy (December 2009), anti-sparganum antibody levels were elevated in the serum (0.29) and in the CSF (0.55, normal value in serum and CSF < 0.22). After therapy (June 2011), antibody levels had dropped to 0.09 in serum (a lumbar puncture was not repeated after therapy). Seizures discontinued and anticonvulsive treatment was slowly tapered.

Discussion:

Sparganosis is a rare parasitic disease caused by infestation with the larval cestode of *Spirometra* spp. Most cases have been reported in Southeast and Eastern Asia. Humans are infected through drinking unfiltered contaminated water or through consumption of raw snakes and frogs. When the parasite invades the central nervous system, epileptic seizures and headache are common symptoms [2]. Characteristic MRI findings of cerebral sparganosis include a 'tunnel sign', and 'wandering lesions' on successive images representing the track of motion of the parasite [6-7].

The treatment of choice for cerebral sparganosis is surgical removal because treatment with antihelmintics, including praziquantel, has been described as not effective [1-3]. In our patient the clinical improvement, and the normalisation of brain imaging and of anti-sparganum antibody levels suggest that the parasite was eradicated by high dose praziquantel therapy. Although the close temporal correlation of therapy and presumed death of the parasite suggests a causal relationship we cannot rule out the possibility that this was, in fact, due to a coinciding, natural death of the parasite and not due to the chemotherapeutics. There is no information regarding the cestode's life expectancy in human tissue in the literature.

Cerebral sparganosis should be suspected in patients from endemic areas with indications of cerebral parasitic infection and "wandering lesions" in the MRI. High-dose praziquantel treatment may be considered in inoperable cases of cerebral sparganosis. Ethylcholine PET can be used preoperatively for the precise localization of the sparganum. This should be particularly valuable if the precise location is not known due to the often multifocal lesions in MRI.

Figure Legend

Radiology findings. The upper and middle row show axial brain MRIs in chronological order. The upper row shows contrast-enhanced horizontal T1-weighted sections (A - F). The middle row shows the corresponding T2 sections (G - L). Characteristic punctate calcifications in the CT in the affected region are shown in M. Repeated ethylcholine PET scans before and 3 and 11 months after praziquantel therapy are shown in N, O, and P. The relative amount of tracer uptake is color-coded with arbitrary units.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

1. Deng L, Xiong P, Qian S (2011) Diagnosis and stereotactic aspiration treatment of cerebral sparganosis: summary of 11 cases. *J Neurosurg* 114 (5):1421-1425.
2. Kim DG, Paek SH, Chang KH, Wang KC, Jung HW, Kim HJ, Chi JG, Choi KS, Han DH (1996) Cerebral sparganosis: clinical manifestations, treatment, and outcome. *J Neurosurg* 85 (6):1066-1071.
3. Torres JR, Noya OO, Noya BA, Mouliniere R, Martinez E (1981) Treatment of proliferative sparganosis with mebendazole and praziquantel. *Trans R Soc Trop Med Hyg* 75 (6):846-847
4. Sotelo J, Jung H (1998) Pharmacokinetic optimisation of the treatment of neurocysticercosis. *Clin Pharmacokinet* 34 (6):503-515
5. Kong Y, Kang SY, Cho SY (1991) Single step purification of potent antigenic protein from sparganum by gelatin-affinity chromatography. *Kisaengchunghak Chapchi* 29 (1):1-7
6. Song T, Wang WS, Zhou BR, Mai WW, Li ZZ, Guo HC, Zhou F (2007) CT and MR characteristics of cerebral sparganosis. *AJNR Am J Neuroradiol* 28 (9):1700-1705.
7. Chang KH, Chi JG, Cho SY, Han MH, Han DH, Han MC (1992) Cerebral sparganosis: analysis of 34 cases with emphasis on CT features. *Neuroradiology* 34 (1):1-8

Figure
[Click here to download high resolution image](#)

